天華超淨(300390.SZ):控股子公司天宜鋰業簽署鋰精礦承購協議 每年購買20萬(±12.5%)幹公噸鋰輝石精礦
格隆匯3月30日丨天華超淨(300390.SZ)宣佈,2021年3月29日,公司控股子公司天宜鋰業作為買方與賣方Dathcom及銷售代理AVZ簽訂《承購協議》。
天宜鋰業主要生產電池級氫氧化鋰,為保障上游優質鋰精礦資源的長期、穩定供應,以滿足後期生產擴大需求,天宜鋰業與AVZ進行戰略合作,向其採購鋰輝石精礦,首期採購期限自Dathcom開始供貨之日起3年,到期後買方可以選擇再延長2年。天宜鋰業同意每年購買20萬(±12.5%)幹公噸的鋰輝石精礦。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.